Tang C, et al. - Since high-dose chemotherapy and autologous stem cell transplant (ASCT) remains a key treatment strategy in patients with relapsed/refractory (R/R) aggressive lymphoma, researchers compared the efficiency, resource use and ASCT outcomes of PBSC mobilisation with gemcitabine, dexamethasone and cisplatin (GDP) to cyclophosphamide + etoposide (CE). Participants in the study were all patients undergoing PBSC mobilization following salvage GDP for R/R lymphoma from 1/2012 to 8/2018. According to findings, CE+GCSF seems to be a more efficient mobilization method than GDP+GCSF with regard to the number and timing of leukapheresis in patients undergoing GDP salvage for R/R lymphoma. This did not, however, translate into significant differences in hospital admission engraftment or length.